Skip to main content
    A

    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $21.23
    -0.15 (-0.70%)

    Market Cap: $7.45B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    Amneal Pharmaceuticals, Inc. Class A Common Stock reported revenue of $3.02B for the fiscal year ended Dec 31, 2025, up 8.0% from the year before. That year, net income was $127.93M with a net margin of 4.2%, operating cash flow was $339.99M and free cash flow was $241.15M. The quarter ended Sep 30, 2026 had revenue of $862.68M and net income of $12.31M.

    Revenue and Margins

    The operating margin was 13.1% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $1.02B, a compound annual rate of 12.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$3.02B+8.0%36.9%13.1%4.2%
    Dec 2024$2.79B+16.7%36.5%8.9%-2.6%
    Dec 2023$2.39B+8.2%34.3%8.5%-2.0%
    Dec 2022$2.21B+5.7%35.5%-4.3%-11.5%
    Dec 2021$2.09B+5.1%36.7%7.3%1.0%
    Dec 2020$1.99B+22.5%31.5%4.6%3.4%
    Dec 2019$1.63B-2.2%21.7%-15.3%-37.1%
    Dec 2018$1.66B+60.9%43.1%-1.2%-12.1%
    Dec 2017$1.03B+1.5%50.9%23.7%16.4%
    Dec 2016$1.02BN/A58.7%28.0%20.6%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income fell 32.1% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$3.02B$2.79B$2.39B$2.21B$2.09B$1.99B$1.63B$1.66B$1.03B$1.02B
    Cost of revenue$1.91B$1.77B$1.57B$1.43B$1.32B$1.36B$1.27B$946.59M$507.48M$420.77M
    Gross profit$1.11B$1.02B$820.57M$784.71M$768.97M$628.39M$353.00M$716.40M$526.18M$597.46M
    Research and development$193.81M$196.56M$167.78M$200.05M$201.85M$179.93M$188.05M$194.19M$171.42M$179.02M
    Operating income$394.10M$249.33M$204.37M-$94.93M$152.72M$91.16M-$248.68M-$19.67M$245.10M$284.88M
    Net income$127.93M-$73.88M-$48.72M-$254.79M$20.17M$68.58M-$603.57M-$201.30M$169.32M$209.43M
    EBITDA$657.67M$468.87M$452.11M$159.31M$410.30M$354.28M$198.07M$114.20M$295.44M$306.12M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$862.68M$796.20M$722.52M$814.32M$784.51M$724.51M$695.42M$730.52M$702.47M$701.78M$659.19M$616.98M
    Gross profit$334.12M$334.51M$320.11M$297.19M$273.97M$286.25M$255.89M$262.87M$269.56M$249.95M$238.06M$189.83M
    Operating income$95.42M$129.77M$141.77M$112.03M$70.34M$111.37M$100.35M$75.79M$88.81M$95.47M-$10.75M$14.19M
    Net income$12.31M$69.61M$78.00M$49.57M$18.13M$35.61M$24.62M-$20.74M$11.76M$16.79M-$81.68M-$93.34M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $2.57B exceeded cash and equivalents by $2.29B. Shareholder equity was negative, at -$70.79M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$3.68B$3.50B$3.47B$3.80B$3.94B$4.01B$3.67B$4.35B$1.34B$1.22B
    Current assets$1.91B$1.59B$1.38B$1.41B$1.52B$1.55B$1.21B$1.29B$771.93M$726.11M
    Cash and equivalents$282.03M$110.55M$91.54M$25.98M$247.79M$341.38M$151.20M$213.39M$74.17M$27.37M
    Total liabilities$3.67B$3.55B$3.41B$3.59B$3.56B$3.65B$3.32B$3.46B$1.72B$1.39B
    Short-term debt$6.76M$324.21M$213.13M$89.96M$30.61M$45.23M$21.48M$21.71M$89.48M$36.98M
    Long-term debt$2.57B$2.16B$2.43B$2.59B$2.72B$2.77B$2.61B$2.63B$1.36B$813.54M
    Shareholder equity-$70.79M-$109.27M$19.78M$298.42M$360.34M$303.27M$232.01M$504.75M-$385.74M-$185.29M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$5.27B$3.78B$3.54B$3.68B$3.60B$3.42B$3.37B$3.50B$3.46B$3.51B$3.46B$3.47B
    Total liabilities$4.63B$3.66B$3.50B$3.67B$3.64B$3.47B$3.42B$3.55B$3.49B$3.51B$3.47B$3.41B
    Cash and equivalents$157.40M$127.64M$197.66M$310.87M$201.25M$71.54M$59.19M$110.55M$74.01M$43.77M$46.52M$91.54M
    Shareholder equity$531.26M$33.02M-$45.41M-$70.79M-$109.46M-$112.12M-$131.67M-$109.27M-$93.43M-$57.47M-$63.72M$19.78M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 70.9% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$339.99M$295.10M$345.58M$65.10M$241.82M$379.00M$1.71M$250.23M$234.19M$115.06M
    Capital expenditures$98.84M$60.34M$46.80M$48.80M$50.94M$61.84M$47.18M$83.09M$94.77M$122.76M
    Free cash flow$241.15M$234.76M$298.78M$16.30M$190.88M$317.17M-$45.48M$167.14M$139.42M-$7.70M
    Dividends paidN/AN/AN/A$17.56M$57.13M$3.24M$0$182.64M$376.13M$201.59M
    Share repurchasesN/AN/AN/A$1.72M$0$0N/A$11.78M$0$5.00K
    Investing cash flow-$112.26M-$63.00M-$69.19M-$174.31M-$194.18M-$317.55M-$19.58M-$396.38M-$98.55M-$124.61M
    Financing cash flow-$31.53M-$211.79M-$212.57M-$106.62M-$138.12M$131.81M-$45.83M$287.68M-$95.02M-$19.50M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$98.30M-$21.24M-$26.74M$130.31M$118.45M$83.82M$7.41M$118.08M$141.77M$39.66M-$4.41M$135.82M
    Capital expenditures$39.58M$45.59M$13.86M$43.17M$15.05M$26.50M$14.12M$22.46M$17.11M$10.70M$10.06M$11.79M
    Free cash flow$58.72M-$66.84M-$40.60M$87.15M$103.40M$57.32M-$6.71M$95.61M$124.66M$28.95M-$14.47M$124.03M
    Last 12 quarters

    Frequently Asked Questions About AMRX

    What is Amneal Pharmaceuticals, Inc. Class A Common Stock's annual revenue?

    Amneal Pharmaceuticals, Inc. Class A Common Stock reported revenue of $3.02B for the fiscal year ended Dec 31, 2025.

    How fast is Amneal Pharmaceuticals, Inc. Class A Common Stock's revenue growing?

    Revenue was up 8.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 10.9%.

    Is Amneal Pharmaceuticals, Inc. Class A Common Stock profitable?

    Yes. Amneal Pharmaceuticals, Inc. Class A Common Stock reported net income of $127.93M for the fiscal year ended Dec 31, 2025, with a net margin of 4.2%.

    How much free cash flow does AMRX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $339.99M minus capital expenditures of $98.84M produced free cash flow of $241.15M.

    How much debt does Amneal Pharmaceuticals, Inc. Class A Common Stock have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $2.57B, short-term debt of $6.76M and cash and equivalents of $282.03M.